Safety and survival rates associated with ablative stereotactic radiotherapy for patients with oligometastatic cancer: a systematic review and meta-analysis
Importance The oligometastatic paradigm postulates that patients with a limited number of
metastases can be treated with ablative local therapy to each site of disease with curative …
metastases can be treated with ablative local therapy to each site of disease with curative …
The abscopal effect: a review of pre-clinical and clinical advances
Radiotherapy has been used for more than a hundred years to cure or locally control tumors.
Regression of tumors outside of the irradiated field was occasionally observed and is known …
Regression of tumors outside of the irradiated field was occasionally observed and is known …
Management of salivary gland malignancy: ASCO guideline
JL Geiger, N Ismaila, B Beadle, JJ Caudell… - Journal of Clinical …, 2021 - ascopubs.org
PURPOSE To provide evidence-based recommendations for practicing physicians and
other healthcare providers on the management of salivary gland malignancy. METHODS …
other healthcare providers on the management of salivary gland malignancy. METHODS …
Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: a prospective, registry-based, single-arm, observational, evaluation study
A Chalkidou, T Macmillan, MT Grzeda… - The lancet …, 2021 - thelancet.com
Background Stereotactic ablative body radiotherapy (SABR) is increasingly being used to
treat oligometastatic cancers, but high-level evidence to provide a basis for policy making is …
treat oligometastatic cancers, but high-level evidence to provide a basis for policy making is …
Single-fraction vs multifraction stereotactic ablative body radiotherapy for pulmonary oligometastases (SAFRON II): the trans tasman radiation oncology group 13.01 …
Importance Evidence is lacking from randomized clinical trials to guide the optimal approach
for stereotactic ablative body radiotherapy (SABR) in patients with pulmonary …
for stereotactic ablative body radiotherapy (SABR) in patients with pulmonary …
Advances in breast cancer radiotherapy: implications for current and future practice
C Shah, Z Al-Hilli, F Vicini - JCO oncology practice, 2021 - ascopubs.org
Radiation therapy (RT) is an essential component in the management of breast cancer.
Following breast-conserving surgery (BCS), adjuvant RT is the standard of care for most …
Following breast-conserving surgery (BCS), adjuvant RT is the standard of care for most …
Recurrent endometrial cancer: local and systemic treatment options
H Rütten, C Verhoef, WJ van Weelden, A Smits… - Cancers, 2021 - mdpi.com
Simple Summary In this review, we discuss the different treatment strategies in recurrent
endometrial cancer. The incidence of endometrial cancer is rising. The available treatment …
endometrial cancer. The incidence of endometrial cancer is rising. The available treatment …
Biology-guided radiotherapy: redefining the role of radiotherapy in metastatic cancer
SM Shirvani, CJ Huntzinger, T Melcher… - The British journal of …, 2021 - academic.oup.com
The emerging biological understanding of metastatic cancer and proof-of-concept clinical
trials suggest that debulking all gross disease holds great promise for improving patient …
trials suggest that debulking all gross disease holds great promise for improving patient …
Determining lines of therapy in patients with solid cancers: a proposed new systematic and comprehensive framework
The complexity of neoplasia and its treatment are a challenge to the formulation of general
criteria that are applicable across solid cancers. Determining the number of prior lines of …
criteria that are applicable across solid cancers. Determining the number of prior lines of …
Organ at risk dose constraints in SABR: a systematic review of active clinical trials
Purpose Organ at risk (OAR) dose constraints are a critical aspect of SABR treatment
planning. There is limited evidence supporting preferred dose constraints for many OARs …
planning. There is limited evidence supporting preferred dose constraints for many OARs …